Pharmaceuticals News & Press Release Distribution

ImmunoForge Inc. receives U.S. FDA ODD for PF1801

SEOUL, South Korea and SILVER SPRING, Md., Oct. 29, 2021 /PRNewswire/ -- ImmunoForge (Co-CEOsSung-Min Ahn, Kiho Chang), a company specializing in developing new drugs for rare musculoskeletal diseases, has reported that their new drug candidate PF1801 which is in development for treatment of D...

2021-10-29 05:50 4049

Jubilee Biotech has developed JUBIwatch, "Health and Life are now wearable"

SEOUL, South Korea, Oct. 28, 2021 /PRNewswire/ -- Jubilee Biotech, a startup in South Korea, has developed JUBIwatch, a smart watch and medication management platform that uses microneedles to administer exact amounts of medication at set times. "Wearing, setting up, and sending information on m...

2021-10-28 21:00 1587

HanAll Biopharma Reports Third Quarter 2021 Results

* Q3'21 sales of KRW 25.5 billion increased 15% from the same period last year * Q3'21 operating profit of KRW 2.2 billion grew by 120% compared to Q3'20 * Nine months sales of KRW 76.7 billion and operating profit of KRW 9.2 billion rose by 15% and 67% YoY, repectively SEOUL, South Korea, Oct...

2021-10-28 21:00 2609

BioVaxys Further Expands Intellectual Property Portfolio in Global Markets

- Files Applications for International Patent and Trademark Protection of CoviDTH VANCOUVER, BC, Oct. 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has broadened the patent coverage on CoviDTH, its T ...

2021-10-28 20:00 3805

Interim report for Q3 2021 : Bactiguard Holding AB (publ)

STOCKHOLM, Oct. 28, 2021 /PRNewswire/ -- Capital injection initiates a new phase of accelerated expansion Third quarter (July-September 2021) * Revenues amounted to SEK 45.2 (34.1) million, an increase of 32%. Adjusted for currency effects revenues increased by 36%. * EBITDA amounted to SEK ...

2021-10-28 15:23 2315

Mallinckrodt and Terumo Blood and Cell Technologies Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Chronic Graft Versus Host Disease (cGvHD) in Adults

– In a dual-review process, two independent advisory committees to the Australian Minister for Health recommended reimbursement based on a favorable clinical and cost-effectiveness comparison – DUBLIN and LAKEWOOD, Colo., Oct. 28, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global ...

2021-10-28 05:48 2728

Launch of Seegene's STARlet-AIOS: All-in-One System Fulfills Critical Need for Fully Automated, High-Throughput Real-Time PCR Testing

* A true walk away 'sample to answer' molecular diagnostic system designed for high throughput testing, offering a time-efficient and seamless workflow for clinical laboratories * Utilizes Seegene's patented, cutting-edge high multiplex real-time PCR technologies to provide 'Real' Ct values...

2021-10-27 23:40 2847

Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), In A Two Drug Regimen, Proves Safe And Effective For Critically Ill Hospitalized AIDS Patients

LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...

2021-10-27 22:08 1961

Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), In A Two Drug Regimen, Proves Safe And Effective For Critically Ill Hospitalized AIDS Patients

LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...

2021-10-27 22:06 1701

Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), In A Two Drug Regimen, Proves Safe And Effective For Critically Ill Hospitalized AIDS Patients

LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...

2021-10-27 22:03 1849

Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Small Cell Lung Cancer in Singapore

- Phase 1b/2 trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration with the Singapore Translational Cancer Consortium - - ADG106 now being evaluated in combinations with three leading anti-PD-1 therapies - SAN DIEG...

2021-10-27 20:52 4461

Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Small Cell Lung Cancer in Singapore

Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), in a Two Drug Regimen, Proves Safe and Effective for Critically Ill Hospitalized AIDS Patients

LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...

2021-10-27 20:47 1429

Qilian International Holding Group Limited Completes Phase One of Its Expansion of New Organic Fertilizer Production Facility and Puts It into Production

JIUQUAN, China, Oct. 26, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), aChina-based pharmaceutical and chemical products manufacturer, today announced that the Company has completed phase one of the expansion of its new organic fertilizer produc...

2021-10-26 20:00 2258

I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its Innovative Assets in China

* I-Mab strategic partnership with Sinopharm will covers all aspects of the go-to-market process, including authorization of more than 300 Sinopharm's subsidiaries as distributors acrossChina. * I-Mab is on track to submit BLA for third line multiple myeloma (MM) treatment by Q4 2021. * The...

2021-10-26 20:00 3238

Samsung Biologics Reports Third Quarter 2021 Financial Results

* Q3'21 revenue of KRW 450.7 billion increased 64% compared to Q3'20. * Q3'21 operating profit of KRW 167.4 billion increased 196% compared to Q3'20. * Stable supply, strong operational excellence and a high utilization rate across all plants. * Active investment on expansion, pre-sales ac...

2021-10-26 15:23 2418

Samsung Biologics Reports Third Quarter 2021 Financial Results

Angel Pharmaceuticals Announces Approval of IND Application in China for ITK Inhibitor CPI-818

JIAXING, China and BURLINGAME, Calif., Oct. 25, 2021 /PRNewswire/ -- Angel Pharmaceuticals Co., Ltd. ("Angel Pharma") today announced that its IND application for CPI-818, a small molecule ITK inhibitor, has been approved by the Center for Drug Evaluation (CDE) to initiate clinical trials in pati...

2021-10-26 07:30 2188

SCN9A Antisense Pain Killer OLP-1002 Moves into Phase 2a Stage

SEOUL, South Korea, Oct. 25, 2021 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to initiate a Phase 2a trial for SCN9A antisense pain killer OLP-1002 inAustralia. In the Phase 2a trial of a two stage adaptive design ...

2021-10-25 20:30 2289

111, Inc. Announces Strategic Partnership with Chugai Pharma China Co., Ltd. to Accelerate Innovations in Chronic Disease Management

SHANGHAI, Oct. 25, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced a strategic cooperation agreement with Chugai Phar...

2021-10-25 19:00 2605

I-Mab Expands U.S. Footprint with New R&D Site in San Diego

- I-Mab will strengthen its global R&D presence, with a new world-class R&D and operational site, located in the heart of the rapidly growingSan Diego biotech hub - The new site will complement I-Mab's Global Clinical Development site in Gaithersburg, Maryland to form an integrated I-Mab US R&...

2021-10-22 20:00 2326

2021 Bio-enzyme Application Explorer Summit held in Chengdu

The event focuses on innovation and development of biochemical pharmaceuticals CHENGDU, China, Oct. 22, 2021 /PRNewswire/ -- The biochemical pharmaceutical industry is facing unprecedented opportunities and challenges with the changing economic and policy environment inChina and abroad. On Octobe...

2021-10-22 14:23 1858